Bio-Techne Corp. - TECH STOCK NEWS

Bio-Techne Corporation (NASDAQ: TECH) announced a new study published in Nature Protocols demonstrating its Namocell^™ Single Cell Dispenser's effectiveness for cloning human pluripotent stem cells (hPSCs). The workflow enhances cell viability and genomic stability, addressing challenges in single cell cloning critical for gene therapy applications. The Namocell system offers a gentle dispensing process, minimizing cell stress and maximizing recovery rates. This innovation positions Bio-Techne to advance hPSC research and applications in regenerative medicine.

Bio-Techne Corporation (NASDAQ: TECH) has opened a new 52,000 sq. ft. product innovation and manufacturing facility in Wallingford, Connecticut, doubling its operational footprint. This facility enhances Ella™ immunoassay cartridge production capacity five-fold, enabling production of up to 500,000 cartridges annually. The expansion, featuring one of the largest cleanrooms in the area, aims to meet the rising global demand for rapid and precise biomarker detection. The Ella assays, developed by R&D Systems, support diverse research areas and are expected to experience continued demand growth.

Bio-Techne Corporation (NASDAQ: TECH) will be presenting at the Stephens Annual Investment Conference on November 17, 2022, at 10:00 a.m. CST. The presentation will be conducted by Jim Hippel, Executive Vice President and Chief Financial Officer. Investors can access a live webcast through the company's Investor Relations website. Bio-Techne is a leader in developing purified proteins and reagent solutions, generating approximately $1.1 billion in net sales in fiscal 2022 and employing about 3,000 people globally.

Bio-Techne Corporation (NASDAQ: TECH) announced that CFO Jim Hippel will present at the Stifel 2022 Healthcare Conference on November 15, 2022, at 2:25 p.m. EST. Interested parties can access a live webcast via the Investor Relations website. Bio-Techne is a leader in developing and manufacturing high-quality proteins, reagents, and diagnostic products, generating approximately $1.1 billion in net sales in fiscal 2022. With around 3,000 employees globally, its offerings are vital for biomedical research and clinical diagnostics.

Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the Credit Suisse 31^st Annual Healthcare Conference on November 9, 2022, at 8:35 a.m. PST. A live webcast will be available on the company's Investor Relations website.

Bio-Techne specializes in manufacturing purified proteins and reagent solutions, generating approximately $1.1 billion in net sales in fiscal 2022, with around 3,000 employees globally. Its diverse portfolio supports biomedical researchers and clinical laboratories.

Bio-Techne Corporation (NASDAQ: TECH) reported a strong performance for Q1 FY2023, with organic revenue growth of 7% to $269.7 million. GAAP EPS rose to $2.21, up from $1.69 last year, supported by gains on investments. The Diagnostics and Genomics segment led the growth with 17% organic growth, particularly from the ExoDx Prostate test, which saw a 70% increase in tests performed and over 100% revenue growth year-over-year. Operating cash flow also improved by 16% to $56.1 million.

Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.32 per share for the quarter ending September 30, 2022, payable on November 28, 2022. Shareholders of record by November 14, 2022, will receive this dividend. Additionally, a four-for-one stock split was approved, providing three extra shares for each held share to those on record by the same date. The split will take effect post-trading on November 29, 2022. Bio-Techne reported approximately $1.1 billion in net sales in fiscal 2022.

Bio-Techne Corporation (NASDAQ: TECH) announced the presentation of its diagnostic lab solutions by Asuragen at the Association for Molecular Pathology (AMP) annual meeting from November 1-5, 2022, in Phoenix, AZ. The company introduced new Armored DNA^™ molecular controls for monkeypox and related viruses to enhance clinical testing capabilities. Workshops and posters will focus on genetic testing workflows and molecular controls for emerging diseases, including SARS-CoV-2. These developments aim to improve lab testing accessibility and response efficiency to public health threats.

Bio-Techne Corporation (NASDAQ: TECH) announced a proof-of-concept study from Exosome Diagnostics, revealing the feasibility of using an exosome-based platform for monitoring astronauts' health in space. The peer-reviewed study, published in npj Microgravity, identifies a potential method to diagnose spaceflight-associated neuro-ocular syndrome (SANS), which affects returning astronauts. Exosomes can be extracted noninvasively from biofluids, offering insights into health changes due to microgravity. This innovative approach aims to enhance astronaut health and has broader applications in precision medicine on Earth.